Center for Biologics Evaluation and Research CBER Vision:2004 - a strategic plan
This article was originally published in Clinica
The FDA's Center for Biologics Evaluation & Research will unveil "CBER Vision:2004", its strategic plan for the next decade, at a vaccines advisory committee meeting this week. CBER director Kathy Zoon is excited about the plan for the agency which regulates a good amount of blood-related technology. Manufacturers of blood washers, warmers and freezers and other equipment used in blood banks; in vitro diagnostics manufacturers whose products are used in screening for manufacturing or transfusion; sources of HIV tests and their associated hardware will all be affected.